Pipeline

The development programs of the company include radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products for treatment of various solid cancers. The companys’s lead candiate Radspherin is currently developed for two indications, peritoneal carcinomatosis from ovarian cancer and from colorectal cancer, but are also relevant for treating other types of cancers. 

The company has developed proprietary antibodies and holds a license for other antibodies. The antibodies are used as targeting modules of the immune-and radioimmunotherapeutic candidates and are currently in a discovery phase. Oncoinvent has a strategy to be a multiple compound company and will continue to focus on developing new product candidates.

 

 

 

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.